Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10188MR)

This product GTTS-WQ10188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12963MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ8380MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ14820MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ11445MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7369MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ13325MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ13511MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW